PT - JOURNAL ARTICLE AU - Ritari, Jarmo AU - Koskela, Satu AU - Hyvärinen, Kati AU - , AU - Partanen, Jukka TI - Phenome-wide HLA association study of Finnish biobank participants reveals infection-autoimmune disease links and modifier effects between HLA genes and alleles AID - 10.1101/2020.10.26.20219899 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.26.20219899 4099 - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219899.short 4100 - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219899.full AB - The human leukocyte antigen (HLA) system is the single most important genetic susceptibility factor for many autoimmune diseases and immunological traits. However, in a range of clinical phenotypes the impact of HLA alleles or their combinations on disease risk is not comprehensively understood.For systematic population-level analysis of HLA-phenotype associations we imputed the alleles of classical HLA genes in a discovery cohort of 146,630 and a replication cohort of 89,340 Finnish individuals for whom SNP genotype data and 3,355 disease phenotypes were available as part of the FinnGen project.In total, 3,649 significant single HLA allele associations in 368 phenotypes were found in both cohorts. In addition to known susceptibility alleles, we discovered a number of previously poorly established HLA associations. For example, DRB1*04:01-DQB1*03:02, a frequent high-risk haplotype for many autoimmune diseases, was also independently associated with infectious diseases. Conditional analyses to distinguish protective effects from nonpredisposition showed that in 21 disease categories the effect of the high-risk allele was significantly decreased by a heterozygoous allele in the same locus. Furthermore, in many immunological diseases the strength of the top risk-allele was significantly modified by an HLA gene of a different class.The results highlight the complex structure of HLA-disease associations and suggest that the entire HLA composition should be considered in genetic risk estimation and functional studies. Independent cross-phenotype HLA class II associations imply pleiotropic effects particularly with autoimmune and infectious diseases, supporting a link between environmental exposure and immunogenetics in these diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Academy of Finland, the Finnish Cancer Association, VTR funding from the Finnish Government, and Business Finland. FinnGen is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl, Genentech Inc, GlaxoSmithKline, Janssen Biotech Inc. Maze Therapeutics Inc., Merck Sharp & Dohme Corp, Novartis, Pfizer Inc., Sanofi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients and control subjects provided informed consent for biobank research in accordance with the Finnish Biobank Act, with the exception of FinnGen legacy samples which were approved by the National Supervisory Authority for Welfare and Health (Valvira). The FinnGen study protocol was approved by the Ethical Review Board of the Hospital District of Helsinki and Uusimaa (Nr HUS/990/2017). The FinnGen study is approved by the Finnish Institute for Health and Welfare (THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3, the 5Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53-1041-17. The Biobank access decisions for FinnGen samples and data for FinnGen data release R5 are: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001. All samples and individual-level data were pseudonymized and processed in accordance with the EU GDPR law.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe FinnGen summary statistics data can be accessed through the Finnish Biobanks’ FinnBB portal (www.finbb.fi).